This is a picture of a gel from the current production run of N6 Vector B. We separate the stock pla ...Read More
Unnatural Selection is a top-rated Netflix original miniseries documenting the beginning of our wor ...Read More
In 2019 Tristan Roberts self-tested an experimental gene transfer mechanism created by biohackers.
We are developing the first open-source horizontal gene transfer protocol for humans. We are starting with genes that confer immunity to disease — broadly neutralizing antibodies. Although we are still in proof of concept stages (with accurate data expected in February 2020) we believe this will be the first functional vaccine for HIV.Become a Partner Clinic
Minicircles are small loops of DNA designed to express proteins for longer and more intensely than traditional plasmids.
Antibodies are large, Y-shaped proteins generated by the immune system to neutralize pathogens. In November 2016 National Institutes of Health discovered N6 and N6-LS, the first broadly neutralizing antibody (bnAbs) against HIV, capable of neutralizing 98.5% of HIV strains. Since then, more effective bnAbs have been found, capable of neutralizing >99.9% of HIV strains.
We incorporate a cocktail of three minicircles expressing three bnAbs.
DNA is complexed with PEI before injection. When transformed in vivo, the vaccine should confer immunity to HIV.
To begin we started with injecting a single minicircle coding for N6. Blood is drawn every week. Because N6 is only capable of neutralizing 98.5% of HIV particles, 1.5% will remain as "escape variants" and this injection cannot cure HIV.
To do the Western Blot and ELISA we need the N6 Antibody Standard, N6 Fab fragment, and N6 anti-idiotype antibody.
To verify antibody production we do the Western Blot (cheaper).
To quantify antibody production over time we do ELISA.
Proving safety and efficacy will require an approved clinical trial, which could take at least two years. You can sign up to be a prospective trial participant.Sign Up To Be A Tester
Our values are global accessibility and eradicationCommit With Us
Interested? Request access below to get additional information